◈ Nootpedia

This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

Compact view
Research pass: thorough Compound WATCH-LIST MEDIUM

Boron

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Editor's verdict WATCH-LIST MEDIUM

Cheap, low-risk testosterone optimizer with the only credible human SHBG/free-T data being Naghii 2011 (n=8, +28% free T, -9% SHBG after 1 week at 6 mg/day) — a small open-label study that has not been independently replicated at scale. For a 20yo MMA athlete already on a comprehensive V4 stack, boron is a low-priority "WATCH-LIST" rather than a default add — modest expected effect size in non-deficient men, brief cycle pattern indicated, and stronger T levers (sleep, body composition, zinc + magnesium + vitamin D adequacy) should be confirmed first. Reasonable to layer in 6-10 mg/day for 1-2 week cycles around bloodwork pulls if labs show high SHBG / low free T despite total T being normal. Hard skip if SHBG is already low.

Research pass: thorough
▸ Decision matrix by user profile Per-archetype
  • 20-30, athletic, peak T, dietary-replete (this-archetype — Dylan)
    LIKELY-SKIP

    Modest evidence, no specific deficit, peak T at age 20, dietary boron from sunflower seeds + raisins + nuts covers needs. Reasonable experimental layer if post-June-bloodwork SHBG is high with suppressed free T despite normal total T. Hard skip if SHBG is normal-low.

  • 18-35 athletic male, no SHBG complaint
    LOW-PRIORITY

    Modest evidence; lower-priority than zinc/Mg/D adequacy. Optional add for a focused libido or hormonal-axis cycle.

  • 30-50 mild SHBG creep, normal total T but low free T
    OPTIONAL-ADD

    Most plausible responder profile per the Naghii mechanism. 6 mg/day × 1-2 week cycles around bloodwork.

  • 40+ aging male, low free T, high SHBG
    POSSIBLE

    Modest expected effect size; cheapest first-line lever before considering TRT/clomid/enclomiphene escalation.

  • Arthritis / OA symptoms (any age)
    POSSIBLE

    Newnham + Pietrzkowski + Yan evidence makes calcium fructoborate (or boron citrate) at 3-6 mg/day continuous a reasonable adjunct. Re-evaluate at 8-12 weeks.

  • Bone density concern (postmenopausal, low BMD, family Hx osteoporosis)
    POSSIBLE

    adjunct. Nielsen 1987 mineral-balance data + plausible vitamin-D-extension mechanism. Pair with D3 + K2 + calcium + resistance training.

  • High-SHBG genotype (rs1799941 / rs6259) or post-23andMe finding
    STRONG-CANDIDATE

    Most likely to show the Naghii-pattern free-T response.

  • Huberman-listener / podcast-driven "T-support" interest
    FRAME HONESTLY

    Evidence base is modest, single small study, no replication. Cheap and low-risk to try; don't expect transformation. Free-fix-first via diet usually adequate.

  • Already on TRT / anastrozole / clomid / enclomiphene
    SKIP

    Hormonal axis is being driven externally; boron adds interpretive noise.

  • Pregnancy / breastfeeding
    HARD-SKIP

    Dietary boron only.

  • CKD (eGFR <60)
    HARD-SKIP

    at supplement doses.

▸ Subjective experience (deep)
  • Onset: Nothing acute. Effects (if any) appear at day 5-10 in users with high baseline SHBG. Day-one users feel nothing — boron is not a stimulant or anxiolytic.
  • Peak / character: No "feel" per se. The most-reported subjective markers are: increased morning erection frequency / quality; modest libido lift; subtle motivational increase that's hard to separate from expectancy. Joint-pain users may notice reduced morning stiffness within 1-2 weeks (Newnham / Pietrzkowski patterns).
  • Plateau: Most users report the effect saturates by week 2-3 and may attenuate by week 4 — consistent with the cyclical pattern recommended below.
  • Negative subjective reports: Dopamine.club aggregates "sexual-side-effects" (36) and "fatigue" (31) as top complaints — likely an estradiol-rise mechanism in high-aromatizers + the SHBG-suppression overshoot in already-low-SHBG users.
  • No stimulant / no sedation: Boron has zero acute psychoactive character. Anyone reporting same-day effects is in placebo territory.
  • Reddit composite: r/PEDs user 425a3064 (5mg twice daily, 2 weeks on / 1 week off, 2022): "Will it be anything spectacular, no it won't. But for about $5 a month I was happy." This is the modal honest report.
▸ Tolerance + cycling deep dive
  • Tolerance pattern: Functional plateau within 2-4 weeks. Not a receptor-level tolerance — the SHBG and inflammation effects appear to saturate as the system reaches a new equilibrium. Continued dosing past the plateau brings no additional benefit, just cumulative tissue boron exposure.
  • Recommended cycle: 1-2 weeks on, 2-4 weeks off. A 4-week-on / 2-week-off pattern is the longer-cycle alternative for joint-focused use.
  • Reset protocol: 2-week washout restores responsiveness in users who feel subjective effect attenuation.
  • No withdrawal syndrome: Stopping boron is pharmacologically uneventful. SHBG and free T return to baseline within 2-4 weeks.
  • Long-term continuous use: No documented harm at 3-6 mg/day continuous over years in dietary intake studies (Iran, Israel population data). The cycling recommendation is about efficacy plateau, not safety.
▸ Stacking deep dive

Synergistic with

  • zinc (10-25 mg/day) — Zinc supports baseline testosterone synthesis and aromatase modulation; boron acts on the free fraction via SHBG. Complementary upstream + free-fraction levers. Dopamine.club's #2 most-combined compound with boron (n=307).
  • magnesium (Mg glycinate / threonate / citrate 200-400 mg) — Magnesium adequacy independently lowers SHBG and improves free T (multiple modest RCTs). Clean co-administration. User already on Mg glycinate + threonate per V4 stack.
  • vitamin D3 (2000-5000 IU/day, with 25(OH)D target 40-60 ng/mL) — Vitamin D status is a stronger lever for total T than boron. Boron also supports vitamin D activation indirectly via 24-hydroxylase modulation. Dopamine.club's #1 most-combined (n=331). Pretty much non-negotiable as a stacking floor.
  • vitamin K2 (MK-7) — Counterbalances calcium directionality when D3 + boron are stacked; classic Reddit "D3 + K2 + boron + magnesium" pattern. Dopamine.club #3 (n=211).
  • ashwagandha (KSM-66, 600 mg/day) — Cortisol-axis lever (independently lowers SHBG via cortisol reduction) + boron's SHBG-uncoupling lever target the same endpoint via different mechanisms. Dopamine.club n=118.
  • tongkat ali (Eurycoma longifolia, 200-400 mg standardized) — Eurycomanone increases free T via similar SHBG-modulation. Boron + tongkat is a popular synergy stack. Dopamine.club n=145.
  • shilajit (fulvic acid + minor minerals) — Possible T-supportive effect; trace mineral profile complements boron. Dopamine.club n=116.
  • creatine monohydrate (3-5 g/day) — Neutral co-administration; creatine has independent DHT-modest effect via tissue conversion. Dopamine.club n=192.
  • omega-3 EPA/DHA — Anti-inflammatory synergy. Dopamine.club n=186.
  • l-tyrosine — Catecholamine substrate; mechanistic-neutral but complementary for performance/focus context.

Avoid stacking with

  • anastrozole / aromatase inhibitors — Boron raises E2 modestly; AIs crash it. Directional opposition makes interpreting either lever harder. Not strictly contraindicated but easier to use one at a time.
  • High-dose calcium fructoborate plus separate calcium supplementation (>1.5 g/day total elemental Ca) — Compounded calcium load without proportional benefit; risk of arterial calcification if K2 is absent.
  • TRT / exogenous testosterone — Boron's SHBG effect is redundant; exogenous T already saturates the system. Adds noise to bloodwork interpretation.

Neutral / safe co-administration

All other V4 / V5 stack compounds (NAC, citicoline, DHA, phosphatidylserine, curcumin, rhodiola, theanine, glycine, beta-alanine, vitamin C, modafinil, bromantane, Adamax / Semax / Selank, ALCAR, apigenin, taurine, astaxanthin, agmatine). No documented interactions.

▸ Drug interactions deep dive
  • No significant CYP interactions. Boron is not a CYP substrate, inducer, or inhibitor.
  • No protein-binding displacement issues with warfarin, phenytoin, valproate, or other narrow-therapeutic-index drugs.
  • Estrogen / hormone therapy: Compounded effect on estradiol; monitor E2 in users on exogenous estrogen or in cycle-support contexts.
  • Loop / thiazide diuretics: May alter renal boron clearance modestly. Not clinically significant at supplement doses.
  • Renal impairment: Boron is renally cleared; significant CKD (eGFR <60) can let plasma boron accumulate. Avoid.
  • Riboflavin (vitamin B2): Boron and riboflavin form a transient complex in vitro; clinically negligible at supplement doses but separates dose timing by 2 hours if both at high doses.
▸ Pharmacogenomics
  • No actionable boron-specific pharmacogenomic variants at supplement doses.
  • SHBG SNPs (rs1799941 G>A, rs6259 Asp327Asn): Determine baseline SHBG levels. Users with high-SHBG genotypes are the most plausible responders to boron's SHBG-uncoupling effect. The user's 23andMe raw data (June 2026) will surface these — relevant for the decision matrix below.
  • CYP19A1 (aromatase) variants (rs700518, rs10046): Aggressive aromatizers may experience disproportionate estradiol rise on boron and should monitor E2 directly or skip.
  • CYP17A1 variants: Animal data (Abdel-Wahab 2022) suggest boron may modulate CYP17A1 expression. Human CYP17A1 SNPs (rs743572) affect androgen biosynthesis; whether boron-response varies by genotype is unstudied.
  • VDR (vitamin D receptor) variants: Boron's interaction with vitamin D activation pathways may show genotype-dependent response; speculative.
▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
OTC boron capsule NOW Foods Boron 3 mg ~$8 / 100 caps high Generic, GMP, third-party tested. Standard pick. 6 mg = 2 caps.
OTC boron capsule Doctor's Best Boron 6 mg (boron glycinate) ~$10 / 60 caps high Glycinate form; single-cap dose. Slightly higher cost per mg.
OTC calcium fructoborate FruiteX-B (Designs for Health / Jarrow) ~$20-30 / 90 caps high Patent form with the most modern joint-RCT data (Pietrzkowski 2014). Higher cost.
OTC calcium fructoborate Solgar Boron Citrate 3 mg ~$10 / 100 caps high Citrate form, single-cap 3 mg.
Bulk powder Bulk Supplements boric acid / sodium borate ~$10 / 100 g medium Cheapest per mg; requires careful gram-scale weighing. Boric-acid taste and form less convenient. USP-grade only.
Dietary (free) Raisins, prunes, almonds, hazelnuts, avocado, leafy greens, sunflower seeds n/a high ~1 cup of raisins ≈ 3 mg boron. Dietary intake of 3-10 mg/day is achievable without supplements. Free-fix-first option for the user.

For the user: Default skip on the OTC bottle. The dietary fix — sunflower seeds, raisins, almonds, leafy greens — covers the realistic upside without the cost or YAML clutter. If the post-bloodwork SHBG indicator triggers, NOW Foods Boron 3 mg × 2 caps AM × 7-14 days is the cheapest experimental layer.

▸ Biomarkers to track (deep)
  • Baseline (before any cycle):
    • Total testosterone, free testosterone (LC-MS preferred over immunoassay), SHBG, estradiol (sensitive LC-MS assay if possible — standard ECLIA over-reads in men)
    • hsCRP, IL-6 (optional — useful for joint/inflammation use case)
    • 25-hydroxy vitamin D, serum magnesium (rule out cheaper-fix deficits before adding boron)
    • Serum calcium, phosphate (mineral-balance baseline)
    • eGFR / serum creatinine (CKD exclusion)
  • During use (week 1, week 4):
    • Re-pull SHBG + total T + free T at week 1 (Naghii window — captures the +28% free T / -9% SHBG signal if it's going to appear)
    • Re-pull SHBG + free T + E2 at week 4 to confirm reversibility or plateau
    • hsCRP at week 4 for inflammation endpoint
  • Post-cycle (2-4 weeks off):
    • SHBG and free T returning to baseline within 2-4 weeks confirms the lever is reversible and real
    • If SHBG stays suppressed long after cessation, the effect was either (a) coincidental or (b) genuinely durable — repeat cycle to disambiguate
  • Optional / specialty:
    • Urinary boron (rarely indicated; useful only for ruling out industrial-exposure confound)
    • 24-hour urinary calcium / magnesium (Nielsen-style mineral balance, mostly research)
    • WOMAC / VAS pain scores for joint-symptom users
  • For the user specifically: Wait for the June 2026 bloodwork (total T, free T, SHBG, E2, hsCRP, 25(OH)D, lipids) before any boron decision. If SHBG >50 nmol/L and free T below midrange, run a 14-day cycle and re-pull at day 14. Otherwise, default skip.
▸ Controversies / open debates Live debate
  • Sample size and replication of Naghii 2011: The entire "boron is a T booster" claim rests on n=8, open-label, 1-week trial. Despite the supplement being sold for 15+ years on this basis, no large modern RCT has been run. Naghii himself published multiple follow-ups but never with adequate n. This is the single largest gap in the boron literature.
  • Effect in already-replete men: Most boron trials are in mixed-status or borderline-deficient populations. Whether men with adequate dietary boron (>2 mg/day from food) and normal SHBG see any free-T effect is unclear — likely small to none.
  • Total T vs free T conflation in marketing: "Boron raises testosterone 28%" supplement marketing collapses Naghii's free-T finding into a total-T claim that the data doesn't support. Total T in Naghii moved modestly and inconsistently.
  • Estradiol direction: Boron raises E2 modestly. For users with low E2 (joint, mood, libido benefit), this is desirable. For high-aromatizers, it's a drawback. Marketing rarely mentions this.
  • Joint / OA evidence age: Newnham's foundational work is 30+ years old; Pietrzkowski 2014 is the only modern RCT and used a specific (patented) form. Whether plain boron citrate matches calcium fructoborate's joint-specific signal is uncertain.
  • Calcium fructoborate vs plain boron: Patent-form marketing claims superiority for joint use, supported by Pietrzkowski and Yan but never head-to-head against plain boron citrate at matched elemental doses. Honest answer: probably modestly better for joint endpoints, equivalent for hormonal endpoints, costs 3x more.
  • Optimal cycle pattern: Anecdotal evidence supports brief cycles, but no formal pharmacokinetic / dose-response study exists. The "1-2 weeks on, 2-4 weeks off" recommendation is community-derived, not data-driven.
  • Reproductive toxicity at high doses: Hadrup 2021 toxicology review confirms benign profile at OTC doses, but the animal-data toxicity signal at >20-100 mg/kg/day occasionally surfaces in popular health writing as evidence against supplementation. Honest framing: irrelevant at 6 mg/day; relevant at industrial-exposure or gram-level doses.
  • Huberman framing (2022 podcast popularization): Huberman's coverage of boron in 2022 as one of the "T support" candidates drove a sales surge but conflated the modest effect size with stronger marketing claims. Frame honestly: cheap, low-risk, modest evidence, useful in specific deficit profiles.
  • Industrial boron exposure vs supplement boron: Borate mine workers (multi-mg/kg cumulative exposure) show no fertility or reproductive harm in occupational epidemiology (multiple cohort studies), reinforcing the benign safety profile at supplement doses.
▸ Verdict change log
  • 2026-05-14 — Maintained: WATCH-LIST / MEDIUM confidence (graduated to thorough research-pass). Modern mechanism literature (Abdel-Wahab 2022 CYP17A1, Sevim 2025 miR-21/PTEN/AKT, Yan 2025 Hedgehog/DDIT3, Farrin 2022 weight meta-analysis) adds mechanistic depth but does not change the underlying claim — single small human RCT (Naghii 2011) supports a modest free-T / SHBG / inflammation effect, replication remains absent. Pietrzkowski 2014 confirms joint-comfort signal for calcium fructoborate. Decision matrix and dosing protocols refined. For the user (peak T, dietary-replete, no SHBG complaint): default skip, post-bloodwork-trigger experimental layer reasonable.
  • 2026-05-10 — Initial verdict: WATCH-LIST / MEDIUM confidence. Cheap, low-risk free-T optimizer with thin but suggestive evidence base. Layer in for brief cycles only if SHBG is high; skip if SHBG is already low.
▸ Open questions / gaps Open
  • Modern, adequately-powered (n≥100), placebo-controlled RCT replicating Naghii 2011 in healthy men, stratified by baseline SHBG. The single most important missing study in the boron literature.
  • Dose-response curve at 3 / 6 / 10 / 15 / 20 mg/day in humans (currently a single-point dataset at 10 mg/day).
  • Effect size in men stratified by baseline SHBG genotype (rs1799941 / rs6259).
  • Long-term BMD endpoints in supplemented vs unsupplemented older adults — Nielsen's mineral-balance data is 38 years old without follow-up.
  • Direct human translation of the Abdel-Wahab 2022 CYP17A1 mechanism — is the upstream-synthesis effect real in humans, or only in goats?
  • Head-to-head calcium fructoborate vs plain boron citrate at matched elemental doses for joint endpoints.
  • Optimal cycle pattern — is 1-2 weeks on / 2-4 weeks off actually superior to continuous 3 mg/day, or is the community wisdom an unfalsified meme?
  • Whether the Naghii-pattern free-T response in already-replete men is even reproducible — current best estimate is "smaller than Naghii reported, probably real, exact effect size unknown."

References

Naghii et al. 2011 — Comparative effects of daily and weekly boron supplementation on plasma steroid hormones and proinflammatory cytokines (J Trace Elem Med Biol; PMID 21129941)

pubmed.ncbi.nlm.nih.gov · 2011
View Study

Pizzorno 2015 — Nothing Boring About Boron (Integr Med (Encinitas); PMID 26770156)

pubmed.ncbi.nlm.nih.gov · 2015
View Study

Newnham 1994 — Essentiality of boron for healthy bones and joints (Environ Health Perspect; PMID 7889881)

pubmed.ncbi.nlm.nih.gov · 1994
View Study

Nielsen 1987 — Effect of dietary boron on mineral, estrogen, and testosterone metabolism in postmenopausal women (FASEB J; PMID 3678698)

pubmed.ncbi.nlm.nih.gov · 1987
View Study

Penland 1994 — Dietary boron, brain function, and cognitive performance (Environ Health Perspect; PMID 7889887)

pubmed.ncbi.nlm.nih.gov · 1994
View Study

Examine.com Boron page

examine.com

research aggregator overview

View Source

Latest research

How was your experience with this compound?

Anonymous · one vote per session · results below at 5+ votes.

Loading…
✎

See something off?

Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.

Discussion — click to load ▸
Loading…